103 completed, 38 terminated, 21 active not recruiting, 21 unknown. 208 Phase 2, 36 Phase 1, 6 Phase 3.
Follow Dasatinib: new trials by email Literature Review of Dasatinib trials Research Report on Dasatinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Asciminib Frontline Risk Adapted Dasatinib 80mg QD (5 days per week), Standarc of Care - Chronic Myeloid Leukemia (CML) | Phase 2 | Not yet recruiting | Prof. Dr. med. Andreas Hochhaus | 200 | 2027-01-01 | 2026-09-04 |
| Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Dasatinib, Ropeginterferon alfa-2b (P1101) - Chronic Myeloid Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2026-07-13 | 2026-10-13 |
| Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML Asciminib add-on, Imatinib, Dasatinib - Ph+ Acute Lymphoblastic Leukemia (Ph+ALL), Blastic Transformation of Chronic Myeloid Leukemia | Phase 2 | Not yet recruiting | The University of Hong Kong | 45 | 2026-03-30 | 2026-03-25 |
| Improving Physical Ability and Cellular Senescence Elimination in HIV Dasatinib, Quercetin, Placebo - Dasatinib - HIV, Frailty | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 82 | 2025-12-04 | 2026-11-18 |
| HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies Dasatinib, Venetoclax, Dexamethasone - Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Phase 1 / Phase 2 | Recruiting | Princess Maxima Center for Pediatric Oncology | 26 | 2025-10-01 | 2025-09-16 |
| Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Recruiting | Mayo Clinic | 44 | 2025-09-18 | 2026-08-26 |
| Fortifying Healthy Behaviors, Optimizing Medical Therapies and Enhancing Cognitive Function in Older Adults-pilot Study Risk managment, Dasatinib, Quercetin (dietary supplement) - Aging, Cognitive Decline | Phase 2 | Completed | Washington University School of Medicine | 23 | 2025-07-28 | 2026-08-19 |
| A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy - B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 222 | 2025-05-30 | 2026-10-27 |
| Newly-diagnosed Pediatric T-cell ALL Protocol Venetoclax, Dasatinib, homoharringtonine - Acute Lymphoblastic Leukemia, Childhood Leukemia, Acute Lymphoblastic | Phase 2 / Phase 3 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 610 | 2025-03-11 | 2025-08-26 |
| Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma Dexamethasone, Vincristine, Inotuzumab - Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 128 | 2025-01-23 | 2026-07-16 |
| Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) Dexamethasone, Vincristine, Daunorubicin - T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 100 | 2024-12-27 | 2026-08-10 |
| Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia Dasatinib Pill, Ketoconazole Pill - Chronic Myeloid Leukemia, Chronic Phase | Phase 2 | Unknown | Hospital Universitario Dr. Jose E. Gonzalez | 15 | 2024-11-01 | 2022-12-06 |
| Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE Dasatinib - Acute Myeloid Leukemia | Phase 2 | Suspended | Institut Paoli-Calmettes | 35 | 2024-05-22 | 2026-10-01 |
| Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer Quercetin, Dasatinib, Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum - Triple-negative Breast Cancer | Phase 2 | Unknown | Fudan University | 10 | 2024-05-20 | 2024-07-08 |
| Safety, Tolerance and Antiretroviral Activity of Dasatinib: a Pilot Clinical Trial in Patients With Recent HIV-1 Infection Dasatinib, Placebo - Recent HIV-1 Infection | Phase 2 | Active not recruiting | Eva Bonfill | 24 | 2024-01-26 | 2026-07-06 |
| Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Dasatinib, Ponatinib, Berlin-Frankfurt-Münster Chemotherapy - Acute Lymphoblastic Leukemia | Phase 2 | Withdrawn | University of Michigan Rogel Cancer Center | 2024-01-01 | 2024-02-22 | |
| Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects Lifestyle Intervention, Dasatinib 100 MG, Quercetin 1000mg - Obesity, Healthy Lifestyle | Phase 2 / Phase 3 | Recruiting | Cedars-Sinai Medical Center | 160 | 2023-10-17 | 2026-03-18 |
| Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment Dasatinib 70 mg, Placebo - HIV Infection Primary | Phase 2 | Completed | Fundació Institut Germans Trias i Pujol | 60 | 2023-10-16 | 2025-09-22 |
| Senolytics to Improve Osteoporosis Therapy Dasatinib 100 Mg Oral Tablet, Quercetin 1.250 mg (oral), Nicotinamide Riboside 1g (oral) - Osteopenia, Osteoporosis, Age-related Bone Loss | Phase 2 | Completed | Odense University Hospital | 120 | 2023-09-06 | 2026-10-23 |
| Dasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver Disease Dasatinib 100 MG + Quercetin (1000 MG), Placebo - NAFLD, NASH With Fibrosis | Phase 1 / Phase 2 | Completed | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 30 | 2023-07-05 | 2026-04-15 |
Showing 20 of 208. Sign in to see all of them.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (39) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (28) · Leukemia, Myeloid, Chronic-Phase (19) · Leukemia (18) · Breast Neoplasms (17) · Prostatic Neoplasms (11) · Recurrence (11) · Carcinoma, Non-Small-Cell Lung (8) · Leukemia, Lymphocytic, Chronic, B-Cell (8) · Leukemia, Myeloid, Acute (8) · Neoplasm Metastasis (8) · Lung Neoplasms (7) · Lymphoma (6) · Melanoma (6) · Pancreatic Neoplasms (6)
Bristol-Myers Squibb (31) · National Cancer Institute (NCI) (23) · M.D. Anderson Cancer Center (16) · St. Jude Children's Research Hospital (5) · Duke University (4) · Washington University School of Medicine (4) · Alliance for Clinical Trials in Oncology (3) · City of Hope Medical Center (3) · Kanto CML Study Group (3) · Massachusetts General Hospital (3) · Mayo Clinic (3) · Memorial Sloan Kettering Cancer Center (3) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (2) · Gruppo Italiano Malattie EMatologiche dell'Adulto (2) · H. Lee Moffitt Cancer Center and Research Institute (2)
United States (140) · France (30) · Canada (28) · Italy (26) · Germany (23) · Spain (21) · United Kingdom (17) · Australia (14) · Finland (14) · Belgium (13) · Norway (13) · Sweden (12) · China (11) · Netherlands (11) · South Korea (11)
Ehab Atallah, MD (2) · Eric Lenze, MD (2) · Nicolas Musi, MD (2) · Philip Amrein, MD (2) · Stacy Moulder, MD (2) · Adil Daud, M.D. (1) · Ahmed Aribi (1) · Allen Eng Juh Yeoh, MBBS (1) · Amer Zeidan (1) · Ana Gonzalez-Angulo, MD, MS (1) · Andrej Lissat, MD PhD (1) · Andrew Lassman (1) · Anjali S Advani (1) · Anna Turkina, Professor (1)
PMID 33242441, PMID 34366147, PMID 34687726, PMID 40009460, PMID 41671463, PMID 12011123, PMID 17317857, PMID 19536906, PMID 20466853, PMID 21508120, PMID 21623279, PMID 21623761, PMID 21931113, PMID 21976132, PMID 22915637, PMID 23328954, PMID 23620574, PMID 23652277, PMID 24128713, PMID 24457377, PMID 24727329, PMID 24788563, PMID 25082346, PMID 25170013, PMID 25501110, PMID 25758746, PMID 25761894, PMID 26586415, PMID 26951627, PMID 27133821, PMID 28334439, PMID 28559019, PMID 28566209, PMID 28835440, PMID 29069857, PMID 29121645, PMID 29498925, PMID 29609532, PMID 29618479, PMID 29720733, PMID 29723397, PMID 29812996, PMID 30607629, PMID 30885996, PMID 31171508, PMID 31201085, PMID 31290996, PMID 31542391, PMID 31553487, PMID 31986451
U10CA031946 (4), U10CA180888 (4), 2008 (3), P30CA016672 (3), U10CA032102 (3), U10CA180820 (3), N01CM00071 (2), N01CM62201 (2), N01CM62202 (2), P30CA014599 (2), P30CA015704 (2), P30CA033572 (2), U10CA027469 (2), U10CA180821 (2), U10CA180868 (2)